Donald Trump
Out of context: Reply #5533
- Started
- Last post
- 12,586 Responses
- jonny_quest_lives0
"Remdesivir — If available, we suggest remdesivir for hospitalized patients with severe COVID-19; among such patients, we prioritize remdesivir for those requiring low-flow supplemental oxygen. Remdesivir is a novel nucleotide analogue that has activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro [39]. (See 'Severe (including critical) disease' below.)"
and
Nonsevere COVID-19 – Among hospitalized patients with nonsevere disease, remdesivir may have a modest benefit, but the clinical significance of the benefit is uncertain. In an open-label randomized trial, 584 patients with moderate severity COVID-19 (pulmonary infiltrates on imaging but oxygen saturation >94 percent on room air) were assigned to receive remdesivir for up to 5 days, remdesivir for up to 10 days, or standard of care [47]. By day 11, the five-day remdesivir group had better clinical status according to a seven-point scale compared with standard of care (odds ratio 1.65, 95% CI 1.09 to 2.48). There was not a statistically significant difference at day 11 in clinical status between the 10-day remdesivir group and the standard of care group. Although discharge rates by day 14 were higher with remdesivir (76 percent in each of the remdesivir groups versus 67 percent with standard of care), these differences were not statistically significant. Interpretation of this trial is limited by the open-label design and an imbalance in co-therapies.
- This is my first actual dive into the science... I was always a wear a mask listen to the scientists guys but never bothered reading up on the treatments..jonny_quest_lives
- This guy had every advantage... a whole staff dedicated to his protection... Totally avoidable...jonny_quest_lives